Randomized, multicenter phase III trial comparing adjuvant treatment with PegIntron [peginterferon alpha-2b] over 36 months versus reference treatment with IntronA [interferon alpha-2b] over 18 months in cutaneous melanoma patients AJCC stage II (greater than or equal to 1.5 mm clinically node negative)

Trial Profile

Randomized, multicenter phase III trial comparing adjuvant treatment with PegIntron [peginterferon alpha-2b] over 36 months versus reference treatment with IntronA [interferon alpha-2b] over 18 months in cutaneous melanoma patients AJCC stage II (greater than or equal to 1.5 mm clinically node negative)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2012

At a glance

  • Drugs Interferon alpha-2b; Peginterferon alfa-2b
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Sep 2012 Results published in the European Journal of Cancer.
    • 12 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top